| Cat.No. | Name | Information |
|---|---|---|
| M2411 | Picropodophyllin (AXL1717) | AXL1717 (picropodophyllin, Picropodophyllotoxin, PPP) is a non-competitive, potent, and specific inhibitor of IGF-1Rα/β with IC50 of 1 nM. |
| M2192 | BMS-754807 | Bms-754807 is a potent igf-1r /InsR reversible inhibitor with an IC50 of 1.8 nM/1.7 nM and also inhibits the activity of Met, RON, TrkA, TrkB, AurA and AurB with an IC50 value of 6,44,7,4, respectively. At 9 and 25 nM, it has almost no inhibitory activity against Flt3, Lck, MK2, PKA and PKC. |
| M2025 | PQ401 | PQ401 is an insulin growth factor-1 receptor (IGF-1R) inhibitor. PQ401 inhibits IGF-I-stimulated IGF-IR autophosphorylation with an IC50 of 12.0 μM in a series of studies in MCF-7 cells. PQ401 is effective at inhibiting IGF-I-stimulated growth of MCF-7 cells (IC50, 6 μM). |
| M45208 | GIP, human | GIP, human is a peptide hormone consisting of 42 amino acids that also acts as a promoter of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. In addition, GIP, human acts as an enteric proinsulin hormone released by intestinal K cells in response to nutrient intake. |
| M24540 | Teprotumumab | Teprotumumab (RV001, R1507) is a first-in-class IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research. |
| M14903 | GIP, human TFA | GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. |
| M7685 | Chromeceptin | Chromeceptin inhibits Insulin-like growth factor 2 (IGF2) signaling by a process that begins with chromeceptin binding to multifunctional protein 2 (MFP-2). |
| M7067 | NVP ADW 742 | Nvp-adw742 (ADW742) is an orally active, selective igF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. Nvp-adw742 inhibited insulin receptor (InsR) with IC50 of 2.8 μM. Nvp-adw742 induces multipotent anti-proliferation/pro-apoptosis in tumor cells. |
| M4090 | Ginsenoside-Rg5 | Ginsenoside Rg5 is the main ingredient of red ginseng. Ginsenoside Rg5 blocks the binding of IGF-1 to its receptor with an IC50 of about 90 nM. Ginsenoside Rg5 also inhibited COX-2 mRNA expression by inhibiting DNA binding activity of NF-κB P65. |
| M3744 | NVP-AEW541 | NVP-AEW541 is a novel, potent and selective inhibitor of IGF-IR kinase with IC50 value of 0.086. |
| M3397 | AG-1024 | AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins). |
| M1957 | BMS-536924 | Bms-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC50 of 100 nM and 73 nM, respectively. It also showed moderate inhibitory activity against Mek, Fak and Lck, but almost no inhibitory activity against Akt1 and MAPK1/2. |
| M1821 | OSI-906 | OSI-906 (Linsitinib) is a potent, selective, dual ATP-competitive tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with IC50 values of 35 nM and 75 nM respectively. |
| M1792 | XL228 | XL228 is a potent multikinase small-molecule inhibitor of insulin-like growth factor type 1 receptor (IGF1R). |
| M1717 | GSK1904529A | GSK1904529A selectively inhibits IGF-IR and IR with IC50s of 27 and 25 nmol/L, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity. |
| M57207 | Indirubin Derivative E804 | Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor (IGF1R), with an IC50 of 0.65 μM for IGF1R. |
| M53957 | IGF-I (24-41) | IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. |
| M45119 | VMB-100 | VMB-100 is an engineered mRNA molecule encoding human insulin-like growth factor-1 (IGF-1) that induces IGF-1 expression in human muscle cells. |
| M31080 | NBI-31772 hydrate | NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (Kis=1-24 nM for all six human subtypes). Anxiolytic and antidepressant-like effects. |
| M30698 | AZ12253801 | AZ12253801 is an ATP-competitive IGF-1R tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC50 of 17 nmol/L. The IC50 for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
